Critical Pharmaceuticals has completed second clinical trial on CP024 intranasal growth hormone.
CP024 growth hormone nasal spray was safe and well tolerated in the study that administered six dose levels of CP024 in healthy subjects.
Pharmacokinetics demonstrated by the nasal formulation, which induces insulin-like growth factor (IGF-1) production, is highly reproducible guaranteeing accuracy and ease of dose titration.
Critical Pharmaceuticals CEO Dr Gareth King said, "We are very excited about the latest clinical results with CP024 which provide clear proof of concept for this product, and which will support our search for a suitable development and commercialization partner to progress the product into phase 2/3 clinical studies."
The few mild and transient adverse events were observed, which are comparable to over the counter marketed nasal products.